{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:07:14Z","timestamp":1791104834235,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1053\/sarh.2001.23499","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T03:46:10Z","timestamp":1030247170000},"page":"12-20","source":"Crossref","is-referenced-by-count":46,"title":["Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis"],"prefix":"10.1053","volume":"31","author":[{"given":"Gerard","family":"Espinosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"T\u00e0ssies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Mu\u00f1oz-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Ordinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Carles","family":"Reverter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Ingelmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/sarh.2001.23499_bib1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":"Permanent visual loss and cerebrovascular accidents in giant cell arteritis","volume":"41","author":"Gonz'lez-Gay","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2001.23499_bib2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-83-6-806","article-title":"Large artery involvement in giant cell (temporal) arteritis","volume":"83","author":"Klein","year":"1975","journal-title":"Ann Intern Med"},{"key":"10.1053\/sarh.2001.23499_bib3","first-page":"359","article-title":"Late thrombotic events in patients with temporal arteritis and anticardiolipin antibodies","volume":"8","author":"Cid","year":"1990","journal-title":"Clin Exp Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02032099","article-title":"Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations","volume":"4","author":"Font","year":"1989","journal-title":"Clin Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib5","first-page":"474","article-title":"Anticardiolipin antibodies in polymyalgia rheumatica-giant cell arteritis: association with severe vascular complications","volume":"90","author":"Espinoza","year":"1991","journal-title":"Am J Med"},{"key":"10.1053\/sarh.2001.23499_bib6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/rheumatology\/33.7.648","article-title":"Prevalence and evolution of anticardiolipin antibodies in giant cell arteritis during corticosteroid therapy. A prospective study of 20 consecutive patients","volume":"33","author":"Kerleau","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib7","first-page":"1694","article-title":"A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis","volume":"22","author":"Chakravarty","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib8","first-page":"541","article-title":"Anticorps anticardiolipine et maladie de Horton","volume":"146","author":"Liozon","year":"1995","journal-title":"Ann Med Interne"},{"key":"10.1053\/sarh.2001.23499_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0197-1859(95)80012-3","article-title":"A more specific ELISA assay for the detection of antiphospholipid antibodies","volume":"15","author":"Harris","year":"1995","journal-title":"Clin Immunol Newsletter"},{"key":"10.1053\/sarh.2001.23499_bib10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1055\/s-0037-1615887","article-title":"Risk factors in venous thrombotic disease","volume":"82","author":"Rosendaal","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1053\/sarh.2001.23499_bib11","first-page":"1184","article-title":"Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions","volume":"16","author":"Hart","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib12","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1182\/blood.V87.6.2314.bloodjournal8762314","article-title":"Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells","volume":"87","author":"Kawai","year":"1996","journal-title":"Blood"},{"key":"10.1053\/sarh.2001.23499_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/ard.52.9.643","article-title":"Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis","volume":"52","author":"Lau","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2001.23499_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.50.5.316","article-title":"Von Willebrandt factor antigen and plasminogen activator inhibitor in giant cell arteritis","volume":"50","author":"Nordborg","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2001.23499_bib15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.56.11.698","article-title":"Long term follow up of von Willebrandt factor and plasminogen activator inhibitor-1 in patients with polymyalgia rheumatica (letter)","volume":"56","author":"Uddhammar","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2001.23499_bib16","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1073\/pnas.92.6.1851","article-title":"Allele-specific increase in basal transcription of the plasminogen-activator inhibitor-1 gene is associated with myocardial infarction","volume":"92","author":"Eriksson","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/sarh.2001.23499_bib17","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1055\/s-0038-1649875","article-title":"Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes","volume":"74","author":"Mansfield","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1053\/sarh.2001.23499_bib18","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/1529-0131(200010)43:10<2349::AID-ANR24>3.0.CO;2-J","article-title":"The 4G\/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene and thrombosis in patients with the antiphospholipid syndrome","volume":"43","author":"T\u00e0ssies","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2001.23499_bib19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2001.23499_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ard.38.5.434","article-title":"An evaluation of criteria for polymyalgia rheumatica","volume":"38","author":"Bird","year":"1979","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2001.23499_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000205234","article-title":"Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens","volume":"17","author":"Clauss","year":"1957","journal-title":"Acta Haematol"},{"key":"10.1053\/sarh.2001.23499_bib22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1055\/s-0038-1649901","article-title":"Criteria for the diagnosis of lupus anticoagulant: an update. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH","volume":"74","author":"Brandt","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1053\/sarh.2001.23499_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ard.49.2.109","article-title":"Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: Prospective analysis of a series of 100 patients","volume":"49","author":"Cervera","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2001.23499_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/rheumatology\/36.1.113","article-title":"Anti-\u03b22 glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome","volume":"36","author":"Teixid\u00f3","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib25","first-page":"632","article-title":"Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome","volume":"85","author":"Mu\u00f1oz-Rodr\u00edguez","year":"2000","journal-title":"Haematologica"},{"issue":"suppl 2","key":"10.1053\/sarh.2001.23499_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0268-9499(96)80042-7","article-title":"NASBA\u00ae factor V Leiden QL, a new genotype assay to detect the factor V Leiden mutation in anticoagulated blood","volume":"10","author":"Roeles","year":"1996","journal-title":"Fibrinolysis"},{"key":"10.1053\/sarh.2001.23499_bib27","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","article-title":"A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis","volume":"88","author":"Poort","year":"1996","journal-title":"Blood"},{"key":"10.1053\/sarh.2001.23499_bib28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/s-0038-1656016","article-title":"An alternative method for PAI-1 promoter polymorphism (4G\/5G) typing","volume":"77","author":"Margaglione","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1053\/sarh.2001.23499_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/rheumatology\/37.2.208","article-title":"Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases","volume":"37","author":"Manna","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib30","first-page":"916","article-title":"Anticardiolipin and antineutrophil antibodies in giant cell arteritis","volume":"17","author":"McHugh","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib31","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/0002-9343(92)90803-J","article-title":"Anticardiolipin antibodies in northern Italian population with PMR\/GCA (letter)","volume":"92","author":"Salvarani","year":"1992","journal-title":"Am J Med"},{"key":"10.1053\/sarh.2001.23499_bib32","first-page":"433","article-title":"Les anticorps anti-cardiolipine dans la maladie de Horton","volume":"143","author":"Liozon","year":"1992","journal-title":"Ann Med Interne"},{"key":"10.1053\/sarh.2001.23499_bib33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/1529-0131(199804)41:4<701::AID-ART18>3.0.CO;2-P","article-title":"Anticardiolipin antibodies and giant cell arteritis","volume":"41","author":"Duhaut","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2001.23499_bib34","first-page":"623","article-title":"The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies","volume":"16","author":"Fields","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0049-3848(00)00243-7","article-title":"High prevalence of protein-dependent and protein-independent antiphospholipid and other autoantibodies in healthy elders","volume":"99","author":"Richaud-Patin","year":"2000","journal-title":"Thromb Res"},{"key":"10.1053\/sarh.2001.23499_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02214942","article-title":"Anticardiolipin antibodies in the polymyalgia rheumatica-temporal arteritis syndromes","volume":"14","author":"McLean","year":"1995","journal-title":"Clin Rheumatol"},{"issue":"suppl","key":"10.1053\/sarh.2001.23499_bib37","first-page":"R47","article-title":"Anticardiolipin antibodies in polymyalgia rheumatica-temporal arteritis (abstract 83S)","volume":"32","author":"Aguilar","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2001.23499_bib38","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/rheumatology\/37.10.1129","article-title":"Absence of anti-\u03b22glycoprotein I antibodies in giant cell arteritis: a study of 45 biopsy-proven cases","volume":"37","author":"Liozon","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib39","first-page":"263","article-title":"Les anticorps anti-cardiolipine et anti-b\u00e9ta-2 glycoprot\u00e9ine 1 (\u03b22 GP1) au cours de la pseudo-polyarthrite rhizom\u00e9lique et de la maladie de Horton. Rev Rhum. [ed","volume":"63","author":"Meyer","year":"1996","journal-title":"Fr."},{"key":"10.1053\/sarh.2001.23499_bib40","first-page":"1104","article-title":"Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus","volume":"25","author":"Bertolaccini","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2001.23499_bib41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/096120339600500511","article-title":"Non-\u03b22-glycoprotein cofactors for antiphospholipid antibodies","volume":"5","author":"Galli","year":"1996","journal-title":"Lupus"},{"key":"10.1053\/sarh.2001.23499_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780400105","article-title":"Disease patterns and tissue cytokine profiles in giant cell arteritis","volume":"40","author":"Weyand","year":"1997","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017201699050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017201699050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T20:21:23Z","timestamp":1581020483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017201699050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["S0049017201699050"],"URL":"https:\/\/doi.org\/10.1053\/sarh.2001.23499","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}